Read the article about Multi-OMICS for Risk Assessment and Progression of Diabetes within the IMI2 project RHAPSODY by Kirsten Leufgen (SCIPROM) and Oliver Uecke (Lipotype GmbH) in the German Magazine Transkript/Laborwelt (04/2017)
Lipotype put online a new biotech & dermatology customer reference with Aldeyra Therapeutics about lipid analysis for topical dermal drug development for the treatment of ichthyosis associated with SLS.
The project in short Sjögren-Larsson Syndrome (SLS) is a rare inborn error of aldehyde metabolism characterized by severe skin thickening (ichthyosis), retinal disease, and neurological dysfunction. As of today, no therapy that addresses SLS has been approved. Aldeyra Therapeutics has conducted a Phase 2 randomized, parallel-group, double-blind, vehicle-controlled, multi-center clinical trial of topical dermal reproxalap for the treatment of ichthyosis associated with SLS. The results of the trial demonstrated clinically meaningful and statistically significant improvements of SLS skin symptoms of patients after only eight weeks of treatment. A multi-center Phase 3 clinical trial is ongoing.
What Lipotype did Lipotype Shotgun Skin Lipidomics provided Aldeyra Therapeutics with lipid analysis of skin samples for identification of relevant lipid biomarkers in the Phase 2 clinical trial. Results of the skin lipidomics analysis delivered evidence for a correlation between clinical effects and those skin lipid biomarkers. Consistent with the clinical activity of reproxalap, significant dermal biomarker changes were noted in reproxalap-treated patients but not vehicle-treated patients. Cholesterol, which is significantly elevated in the skin of SLS patients, was reduced in reproxalap-treated patients more than in vehicle-treated patients.
About Aldeyra Therapeutics Aldeyra Therapeutics is a biotechnology company devoted to improving lives by inventing, developing, and commercializing next-generation medicines that treat immune-mediated and metabolic diseases. Aldeyra’s lead product candidate, reproxalap (formerly called NS2), is a small molecule RASP (Reactive Aldehyde Species) inhibitor in Phase 3 clinical development for the treatment of dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. With its focus on a carefully selected range of diseases, Aldeyra Therapeutics is devoted to improving lives through outstanding innovation.
Every scientist dreams of a report in Science. For us, this dream has just come true. The research project of one of our customers has been published by the iconic journal Science.
The research project in 60 seconds Cell membranes contain a vast range of distinct lipid species. Their chemical differences influence the physical characteristics of membranes, such as viscosity. Thus, the lipid composition affects biological functions.
To identify the lipids involved, the research group used genetic engineering to modulate the lipid composition of bacteria. They correlated bacterial growth rates with lipid composition. From that they concluded that the level of unsaturated lipids influences cellular respiration, the conversion of nutrients into energy (e.g. ATP).
Further biological research and physical modeling confirmed the results. In the end, they could replicate their findings in yeast mitochondria, the organelle responsible for cellular respiration in animals and plants. Thus, further highlighting the importance of lipidomics in fundamental research.
All science is just as good as the research which precedes it This publication has been added to the Lipidomics Resource Center, an online tool to empower your lipid research. It features scientific publications, white papers and industry insights. The integrated live full-text search and in-depth tag filter system will help you identify information of your interest.
Lipids are essential to life. Make them essential to your research too!
Multiomics approaches harness synergies and eliminate shortcomings to effectively deliver what one omics science alone cannot achieve. Lipotype’s new white paper “Unlocking the Power of Multiomics” highlights why combining genomics with lipidomics makes for a great omics pair.
Genomics for genes, lipidomics for lipids Being major players in cardiovascular disease research, genomics and lipidomics are perfectly suited for a joint multiomics approach. It matches the capacity to identify genetic predestinations with one or multiple snapshots of the lipid metabolic status.
Linking genotype with phenotype will be critical when it comes to clinical diagnostics and to the goal of identifying the onsets of a disease.
From genotype to phenotype: interconnected disease risk factors In this study, a large number of SNPs (single-nucleotide polymorphisms) from genomes was drawn. They were then correlated with corresponding lipid species levels from human blood plasma. The blood plasma has been analyzed with Lipotype Shotgun Lipidomics technology. The most important findings are the following.
First, the heritability of lipid species levels was quantified from the SNP correlations. Second, genetic predispositions influencing lipid species levels provide useful information for cardiovascular disease risk predictions. And third, lipidomics yields greater statistical power to identify SNPs with direct roles in lipid metabolism. Lipidomics outperforms traditional lipid panel measures used in clinical routine.
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.